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Treatment of Acute Neuroleptic-Induced Movement 
Disorders 
Margaret E. Tonda, Pharm.D., and Sally K. Guthrie, Pharm.D. 
Acute extrapyramidal syndromes (EPS), including dystonia, parkinsonism, and 
akathisia, are associated with the use of virtually all neuroleptic agents. They 
may be alleviated by reducing the neuroleptic dosage, switching to a lower- 
potency drug, or administering an adjunctive agent such as an anticholinergic, 
amantadine, benzodiazepine, or P-blocker. Akathisia may be only partly 
dispelled by anticholinergics; alternatives are P-blockers, benzodiazepines, and 
clonidine. In patients receiving long-term neuroleptic therapy, both the 
prophylactic use and the duration of treatment with concomitant anti-EPS drugs 
are controversial. Administration of prophylactic anti-EPS drugs should be 
based on the likelihood that the patient will develop EPS, as well as the risk of 
adverse reactions resulting from extended use of the agents in a specific patient. 
The decision to continue anti-EPS therapy should be reevaluated frequently, 
especially in elderly patients. 
(Pharmacotherapy 1994; 14( 51543-560) 
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Conclusion 
Antipsychotic or neuroleptic agents have been 
used in clinical practice for the past 30 years. 
They revolutionized the management of psychoses, 
but they are associated with significant side effects. 
Almost immediately after their introduction, a 
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range of extrapyramidal syndromes (EPS) was 
observed. Although neuroleptics belong to several 
different chemical classes including phenothiazines, 
thioxanthenes, butyrophenones, dihydroindolones, 
dibenzoxazepines, and diphenylbutylpiperidones, 
they are all dopamine antagonists and induce EPS 
to various degrees.', ' Other drugs that cause 
central dopamine receptor blockade, such as 
metoclopramide (an antiemetic) and amoxapine 
(an antidepressant), can also produce extra- 
pyramidal movement  disorder^.^^ 
Antipsychotic-induced EPS fall into four 
categories: parkinsonism-like movements, acute 
dystonia, akathisia, and tardive dyskinesia. This 
article focuses only on the acute movement 
disorders; several excellent reviews have been 
written on tardive dyskinesia.1.5.6 
Pharmacology 
The production of voluntary movement results 
from complex interactions among the motor 
cortex, basal ganglia, and spinal cord. The 
corticospinal, or pyramidal, tract is one of the 
major pathways by which electrical signals are 
conducted from the motor cortex to the anterior 
motor neurons of the spinal cord. Collateral 
pathways split from the corticospinal tract toward 
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the basal ganglia by way of the caudate nucleus 
and putamen, two structures known collectively as 
the neostriatum. The basal ganglia are a collection 
of subcortical and midbrain structures made up of 
the globus pallidus, substantia nigra, neostriatum, 
and subthalamic nucleus. The collateral pathways, 
which travel through the basal ganglia, are 
considered to be separate from the pyramidal tract 
and are called the extrapyramidal tracts. 
The extrapyramidal system modulates and 
modifies the motor signals sent by the corticospinal 
tract. Sensory and motor information travels from 
the cortex to the basal ganglia, where it is integrated, 
refined, and relayed through the thalamus back to 
the prefrontal cortex and, ultimately, the spinal cord 
(Figure l).7 
Dopamine is one of several neurotransmitters 
that act on the extrapyramidal system. At least five 
important dopamine pathways have been 
delineated in the human brain.8 Neuroleptics are 
thought to produce effects on movement primarily 
through their actions on dopamine pathways in the 
basal ganglia, whereas dopamine cell bodies 
located in the substantia nigra or ventral tegmental 
areas that project to the limbic system and the 
cortex (mesolimbic and mesocortical systems) 
appear to affect mood and thought p r o c e ~ s e s . ~  
Neuroleptic effects on movement are thought to be 
mediated primarily by another dopamine pathway, 
the nigrostriatal pathway, which consists of cell 
bodies in the substantia nigra that project to the 
neo~triatum.~ 
In addition to dopamine, the glutamatergic y- 
aminobutyric acid (GABA), acetylcholine, and 
serotonin neurotransmitter systems affect 
extrapyramidal movement. Cortical afferent tracts, 
which are primarily glutamatergic, project into the 
striatum (putamen) where they terminate on GABA 
neurons. The GABA neurons in the putamen then 
project to the globus pallidus, as well as the 
substantia nigra. Glutamate generally acts as an 
excitatory neurotransmitter in the brain, and GABA 
Figure 1. Summary of basal ganglia circuitry. SN = substantia nigra; STR = neostriatum; GPE = globus pallidus externa, GPI = 
globus pallidus interna; STN = subthalamic nucleus; Thal = thalamus; ACh = acetylcholine; DA = dopamine; GABA = y- 
aminobutyric acid; Glu = glutamate; 0 = unknown neurotransmitter; + = excitatory, - = inhibitory. 
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is usually inhibitory. The exact role of GABA is not 
clearly defined, but this neurotransmitter appears 
to maintain normal basal ganglia function through 
a complex system of negative feedback loops. 
Glutamatergic input to the striatum is modulated 
by dopamine neurons originating from the 
substantia nigra, by acetylcholine interneurons in 
the striatum, and by input from other GABA 
neurons within the striatum. Dopamine appears to 
have an overall inhibitory effect on the thalamic 
output to the prefrontal cortex that is antagonized 
by the acetylcholine interneurons in the ~tr ia tum.~ 
Although the mechanism of action of neuroleptic 
agents has not been definitively identified, the 
antipsychotic action of the drugs is thought to 
result from the postsynaptic blockade of dopamine 
receptors in the mesocortical and mesolimbic 
systems.’ Unfortunately, most neuroleptics are 
relatively nonselective with regard to which 
dopamine pathways are affected, and dopamine 
receptors in the striatum are also blocked. This 
causes a relative deficiency of dopaminergic activity 
in the striatum, and a disturbance in the balance 
between striatal dopaminergic and cholinergic 
systems. Neuroleptic-induced EPS may result 
primarily from blockade of dopamine receptors in 
the striatum, but the imbalance between 
acetylcholine and dopamine systems in this area is 
also an important factor. Many treatment regimens 
aim to restore this balance by either reducing 
acetylcholine or increasing dopamine neuro- 
transmission in the striatum. In addition to their 
dopamine receptor-blocking actions, neuroleptic 
agents may also block cholinergic receptors, cx- 
adrenergic receptors, and histaminel receptors.”, l1 
The propensity for a neuroleptic agent to induce 
EPS depends not only on its dopamine receptor- 
blocking potency but also on its inherent 
anticholinergic activity. Neuroleptic agents are 
classified as low or high potency based on their 
degree of dopamine receptor blockade. The high- 
potency agents possess a greater affinity for the 
dopamine receptor and lower cholinergic 
(muscarinic) receptor affinity than the low-potency 
agents; thus they cause a greater disruption in the 
balance between dopamine and acetylcholine, and 
are more likely to result in EPS.lg12 
Numerous dopamine receptor subtypes (D1, D2, 
D3, D4, and Ds) have been found in the central 
nervous system. The D2 receptors are most 
strongly linked to the efficacy of neuroleptic 
agents,12 and their blockade at least partially causes 
movement disorders. The D1 receptors appear to 
modulate the intensity of movement disorders.’, l3 
The actions of the other dopamine receptor 
subtypes are not well characterized. The atypical 
neuroleptic agent clozapine causes almost no EPS 
and exhibits a relatively high affinity for D4 
 receptor^,'^ but at  this time it is not clear if the 
decreased frequency of EPS is related to this 
affinity. Clozapine also has relatively higher affinity 
for muscarinic receptors and has lower occupancy 
of D2 receptors in the basal ganglia compared with 
typical antipsychotics. 15-17 
The exact sites of dopamine-serotonin inter- 
actions that are most relevant to motor control are 
not known, but it appears that serotonin neurons 
projecting from the nucleus raphe dorsalis 
modulate dopamine pathways in the basal 
ganglia.18 Ritanserin, a serotonin type 2 (5-HTz) 
receptor-blocking agent, decreases EPS when given 
to patients receiving neuroleptics without 
concomitant anti-EPS agents.Ig Risperidone, the 
newly marketed atypical neuroleptic, causes fewer 
EPS than the standard neuroleptics and has a high 
affinity for 5-HT2 receptors.20* 21 Clozapine also 
has relatively high affinity for 5-HTz receptors.12. l5 
It is hypothesized that the low frequency of EPS 
associated with these two drugs is due to their 5- 
HT2-blocking action. This argument is particularly 
compelling for risperidone because the drug shows 
virtually no affinity for muscarinic receptors.2’ 
Pathophysiology and Clinical Manifestations of 
Drug-Induced EPS 
Table 1 lists the dopamine receptor-blocking 
potency and relative frequency of adverse effects of 
commonly used neuroleptic agents.l0* l1 The 
frequency of drug-induced EPS varies from 4-50% 
depending on the specific The low- 
potency agents are associated with a higher 
frequency of antiadrenergic (orthostatic hypo- 
tension) and anticholinergic (dry mouth, consti- 
pation, blurred vision) effects and a lower frequen- 
cy of EPS, whereas the reverse is true for the high- 
potency drugs. Although higher dosages of 
neuroleptics are generally associated with a higher 
frequency of EPS, most studies describe profound 
individual variations in susceptibility to drug- 
induced EPS. Thus, drug potency is probably a 
better predictor of EPS potential than dosage. 
Some common problems associated with the 
treatment of these disorders are infrequent or 
incomplete examinations and inadequate dosages 
of anti-EPS agents.28 Also, the relationship 
between the therapeutic and adverse effects of 
neuroleptics is ill defined. Although some 
investigators suggested that the onset of 
neuroleptic-induced EPS may serve as a clinical 
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Table 1. Antipsychotic Agents 
Chemical Class Equivalence (mg) Symptoms Extrapyramidal Anticholinergic 
Pheno thiazines 
Aliphatic type 
Piperidine type 
Piperazine type 
Traditional Sedation Adverse Effects 
Chlorpromazine 100 t++ tt t+t 
Thioridazine 100 +t+ t t+t 
Perphenazine 10 t ttt tt 
Trifluoperazine 5 t t++ t 
Fluphenazine 2 t ttt + 
Nonpheno thiazines 
Thioxanthene 
Thiothixene 
Butyrophenone 
Haloperidol 
Dibenzoxazepine 
Loxapine 
Dibenzazepine 
Clozapine 
Dihydroindolone 
Molindone 
Diphenylbutylpiperidone 
Pimozide 
Benzisoxazole 
Risueridone 
4 
2 
10 
50 
10 
1 
6 
+ 
+ 
tt+ 
ttt 
++ +t 
+tt tf- 
(Low-frequency akathisia) 
t+ ++ 
+ 
+/- 
t++ 
+/- 
+ 
+ 
t+ 
++t 
++ 
+ 
- 
+++ = high; ++ = moderate; + = low, +/- = slight or mild. 
Adapted from references 10.20,21, and 46. 
marker for therapeutic response or adequate serum 
neuroleptic levels, the current consensus is that 
this adverse effect is not linearly correlated with 
therapeutic re~ponse.~ ' -~~ 
Pseudo parkinsonism 
Neuroleptic agents are the major cause of drug- 
induced p a r k i n s ~ n i s m . ~  The most common 
manifestations of this syndrome are bradykinesia, 
resting tremor, and akinesia. Other features are 
masked facies due to rigidity and akinesia of facial 
muscles, slow initiation of motor activity, soft and 
monotonous speech, flexed posture, decreased arm 
swing, and shuffling gait.' The patients usually 
have symmetric akinesia and rigidity, however, in 
the early stages, asymmetric symptoms may 0ccur.l 
Rigidity of the extremities, neck, or trunk may 
appear days to weeks after the onset of bradykinesia. 
Neuroleptic-induced parkinsonism occurs in 
approximately 2040% of all patients treated with 
these drugs and is clinically indistinguishable from 
postencephalitic parkinsonism or idiopathic 
parkinsonism.', 5 ,  33-35 The age distribution of the 
disorder closely parallels that of Parkinson's 
disease, with increased frequency after 40 years, 
perhaps due to decreases in dopamine levels and 
nigral cell counts with advancing age.', 23, 36 
However, drug-induced parkinsonism is also 
patient specific and dose related, and young adults 
and children are occasionally a f f e ~ t e d . ~  This 
condition occurs at various times after initiating 
neuroleptic therapy, but typically within 30-90 
days.23 Severe parkinsonism may also develop 
after the concomitant discontinuation of both 
antiparkinsonian and neuroleptic agents, ' possibly 
because the former are more rapidly eliminated 
from the body The frequency and severity of this 
disorder are dependent on the degree of dopamine 
receptor blockade induced by the neuroleptics in 
the nigrostriatal pathway.', 2 -  Many individuals 
receiving low-potency neuroleptics have a 
therapeutic antipsychotic response without 
extrapyramidal dysfunction, probably due to the 
significant cholinergic receptor blockade caused by 
these drugs. 
Acute Dystonic Reactions 
Acute dystonic reactions occur in 2-10% of 
patients treated with neuroleptic agents.5* 23, 37 
Their frequency is highest among men under age 30 
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years.23 The reactions typically occur within 24-48 
hours after the first dose, but they can also occur or 
recur when dosages are increased.37 The slow- 
release injectable neuroleptics, such as fluphenazine 
decanoate and haloperidol decanoate, usually 
produce reactions within 72 hours after injection.' 
These reactions are of sudden onset and typically 
consist of bizarre movements involving tonic 
contractions of skeletal muscles of the eyes, face, 
neck, and throat.', 38 Common symptoms consist 
of intermittent or sustained muscular spasm 
manifested as torticollis, swollen tongue, trismus, 
and oculogyric crisis, and occasionally opistho- 
tonus can occur.', 23- 37 Torticollis is most frequent 
in  younger people and males, and tends to 
decrease with increasing age.24- 37* 39- 40 
Dystonic reactions most commonly occur when 
neuroleptic-induced postsynaptic dopamine 
blockade is followed by a rapid fall of the 
neuroleptic concentration in the striatum. Based 
on this observation, one theory postulates that the 
reactions are a result of the compensatory release of 
dopamine that is activated when dopamine 
autoreceptors are blocked. Since an increased 
amount of dopamine is present when the 
neuroleptic concentration falls, a dyskinesia similar 
to those caused by levodopa is seen. However, 
studies with drugs that inhibit synthesis of, or 
deplete, dopamine usually find that these agents 
either cause or potentiate dystonic reactions, which 
suggests that the reactions result from a decrease 
rather than an increase of d~pamine.~'  Dopamine 
dysregulation may also lead to changes in the 
cholinergic system, resulting in increased 
cholinergic activity in the basal ganglia. 
Akathisia 
Akathisia is a common and distressing form of 
EPS that can occur within days to months after 
initiating therapy.' It occurs in approximately 20% 
of patients receiving neuroleptic drugs, and the 
frequency ranges from 5-50% or more in patients 
receiving moderate dosages of high-potency 
agents.23* 26 The frequency also increases as the 
dosage is escalated. Akathisia is commonly 
associated with noncompliance and may even lead 
to suicide attempts in some  individual^.^^ 42 
Therefore, early recognition and treatment are of 
great clinical importance. 
The definition of akathisia includes both 
subjective and objective components. The 
subjective component often is a feeling of inner 
anxiety or tension, and the objective component 
includes motoric restlessness, inability to remain 
still, and pacing.'. 2 *  l o *  26 Since akathisia can 
manifest as increased anxiety, it is often difficult to 
distinguish it from re-emerging psychosis or 
anxiety due to underlying psychiatric i l lne~s.~ The 
pathophysiology of akathisia is poorly understood. 
When induced by neuroleptics, it may reflect 
postsynaptic blockade in  the frontal cortex 
innervated by the mesocortical dopamine 
pathway.* Alternatively, i t  may result from 
dysregulation of any of the neuromodulators of this 
pathway, such as norepinephrine or GABA. 
Treatment 
The EPS may be bothersome or unbearable, and 
pharmacologic treatment can improve patient 
compliance with neuroleptic agents.42 Treatment 
may be by any of several different modalities. In 
some cases, EPS may be terminated or decreased 
by reducing the dosage of the neurolepti~.~~. 3 1 9  33 
Switching from a high-potency to a low-potency 
drug that has more anticholinergic activity may 
also decrease EPS.'. 28 If these strategies are 
inappropriate or ineffective, a centrally acting anti- 
cholinergic or dopaminergic agent might be tried.43 
Of all the extrapyramidal reactions, dystonias are 
the most responsive to treatment; they are easily 
controlled by parenteral or oral administration of 
anticholinergics.' Benzodiazepines may also be 
useful in  the treatment of acute dystonias. 
Parkinsonism has been successfully treated with 
anticholinergic and dopaminergic drugs. Several 
drugs are effective in patients with akathisia, 
including anticholinergics, benzodiazepines, 
clonidine, P-adrenergic blockers, amantadine, 
amitriptyline, opioids, and lithium."+- 45 
Anticholinergic Agents 
Parkinsonism 
Table 2 lists the commonly used anti-EPS agents, 
their relative potencies, and usual dosing 
regimens.4G5g Currently available anticholinergics 
do not differ in efficacy, and all decrease rigidity 
more than d l  Although they 
differentially bind to muscarinic receptor subtypes, 
this does not appear to affect their usefulness in 
this settingd2 The primary differences among them 
are their duration of action and extent of sedation. 
Benztropine is typically given 1-3 timedday, and 
diphenhydramine 2-4 timedday. Trihexyphenidyl 
has a shorter duration of effect and tends to be 
dosed 3-4 times/day.28. 63* 64 Diphenhydramine and 
benztropine are quite sedating, but trihexyphenidyl 
may be less ~ e d a t i n g . ~ ~ . ~ ~  
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Table 2. Common Dosages of Anti-EPS Agents 
Daily Dosing 
Dose (mg) Frequency Route Indications 
Anticholinergic Akathisia, acute dystonic 
Benztropine 1-6 q.d.-t.i.d. p.o./i.m./i.v. reaction, parkinsonism 
Diphenhydramine SO-200 b.i.d.-q.i.d. p.o./i.m./i.v. 
Biperiden 2-16 q.d.-t.i.d. p.o./i.m./i.v. 
Trihexyphenidyl 5-15 t.i.d.-q.i.d. p.0. 
Procyclidine 5-30 t.i.d. p.0. 
Dopaminergic 
Amantadine 100-300 
Parkinsonism 
b.i.d.-t.i.d. p.0. 
Benzodiazepines" Akathisia, ?acute dystonic 
Lorazepam 1-5 q.d.-t.i.d.? p.o./i.m./i.v. reaction , 
Diazepam 2-10 t.i.d.? p.o./i.v. 
Clonazepam 0.5-1.5 q.d.-t.i.d.? p.0. 
Propranolol 30-80 b.i.d.-t.i.d. p.0. 
Metoprolol 50-200 b.i.d. p.0. 
P-Blockers Akathisia 
"Dosing frequencies for benzodiazepines are based on the minimal information available. 90-95 
Adapted from references 46-59. 
Acute Dystonic Reactions 
These are often treated with parenteral drugs, 
but many less severe reactions can be managed 
adequately with oral agents, although the onset of 
effect is longer than with parenteral treatment. 
Anticholinergics usually result in improvement 
within 10 minutes of parenteral administration, 
and peak benefits occur within 30 minutes.23 
Comparisons of intravenous and intramuscular 
administration among different anticholinergics in 
acute dystonia have not been published, but 
benefit reportedly occurs more slowly after 
benztropine than di~henhydramine.~~ 
The usual intravenous or intramuscular dose of 
diphenhydramine is 25-50 mg, and for benz- 
tropine 0.5-2 mg; doses may be repeated in 30 
minutes.27 Once the acute dystonia is controlled, 
anticholinergics should be continued orally for at 
least three to' four doses,23 and possibly as long as 
7-28 days.39- 65 Typical therapy consists of oral 
benztropine 1-2 mg 1-3 timedday, or oral 
diphenhydramine 25-50 mg 2-4 times/day.l0- 66 If 
neuroleptic therapy is discontinued, anti- 
cholinergics should be continued for at least 3 days 
and then tapered, because residual dopamine- 
blocking activity may continue.65 The tapering 
schedule should be based on the dosage and 
duration of anticholinergic treatment. Abrupt 
discontinuation of anticholinergic agents in a 
patient who has received large daily doses for a 
prolonged period of time could result in a 
cholinergic rebound syndrome, such as that 
reported after abrupt withdrawal of highly anti- 
cholinergic tricyclic antidepressants such as 
amitri~tyline.~' 
Akathisia 
Dystonias and parkinsonism generally respond 
favorably to anticholinergic agents, but akathisia 
responds less favorably43 Treatment of akathisia 
was evaluated in 44 patients receiving maintenance 
doses of haloperidol 10 mg/day and 67 receiving 
thiothixene 0.44 mg/kg/day Thirty-two patients in 
both groups had akathisia that was treated with 
either benztropine 8 mg/day or trihexyphenidyl 15 
mg/day.68 The presence and severity of akathisia 
were rated on a 7-point involuntary movement and 
extrapyramidal scale formulated by the 
investigators. Akathisia was suppressed in 44% of 
the patients receiving haloperidol and in all but 
three patients receiving thiothixene. The authors 
hypothesized that the refractory akathisia 
experienced by patients receiving haloperidol may 
have been related to unusually ldw anticholinergic 
levels, and speculated that dosages exceeding the 
upper limit recommended by the manufacturer 
might have resulted in a better response. However, 
they did not report how well patients tolerated the 
relatively large dosages of anticholinergics given in 
this study Although some patients might respond 
to high dosages of benztropine or trihexyphenidyl, 
it is likely many would not be able to tolerate the 
associated side effects. 
It was initially observed that anticholinergic 
agents work well in patients whose akathisia is 
accompanied by parkinsonism.26 Two additional 
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studies6'* 70 and one case report4' confirmed this. 
Factors that complicate the comparison of studies 
evaluating anticholinergics in the treatment of 
akathisia include the use of different dosages, 
dissimilar patient populations, and the variety of 
rating scales for EPS. In addition, although drug 
concentrations may affect the therapeutic outcome, 
serum anticholinergic concentrations were 
measured only rarely7' 
Summary 
Although anticholinergic drugs are often 
beneficial in patients suffering from neuroleptic- 
induced EPS, their beneficial effects must be 
considered in balance with their bothersome 
peripheral side effects such as dry mouth, blurred 
vision, tachycardia, urinary retention, and 
constipation. Since anticholinergic effects are 
additive, combinations of psychotropic agents with 
anticholinergic properties may produce an anti- 
cholinergic delirium, characterized by halluci- 
nations, delusions, and confusion.61 This adverse 
event, which seems particularly prominent in the 
elderly, may be misdiagnosed as an acute episode 
of psychosis. When administered in the short 
term, anticholinergics decrease performance on 
tests of memory acquisition in both schizophrenic 
patients and healthy controls.72- 73 In addition, 
many elderly patients with neuroleptic-induced 
parkinsonism may show clinical signs of dementia, 
and further decrements in central acetylcholine 
neurotransmission may cause significant 
impairment in cognitive function.' 
These drugs also affect the psychotic process. 
They weakly antagonize the beneficial effects of 
neuroleptics on positive symptoms74 and worsen 
positive symptoms in otherwise drug-free 
schizophrenic 76 Conversely, they may 
have beneficial effects on negative schizophrenic 
symptoms,77. 78 and their withdrawal may 
occasionally result in worsening of the clinical 
state.79 Consequently, the clinical response after 
adding or withdrawing an anticholinergic from the 
drug regimen of a schizophrenic patient must be 
closely monitored. 
Dopaminergic Agents 
Parkinsonism and Akathisia 
The most direct approach to the treatment of 
parkinsonian symptoms is to increase striatal 
dopamine neurotransmission. In Parkinson's 
disease this is accomplished with a dopamine 
precursor (L-dopa), a direct dopamine agonist 
(bromocriptine), or an indirect agonist (amanta- 
dine). The action of r-dopa in drug-induced EPS 
was evaluated in 20 schizophrenic patients who 
were receiving antiparkinson therapy for EPS.80 
Patients were tapered off their anti-EPS drug before 
initiating therapy with L-dopa. Sixteen patients 
developed severe deterioration in psychomotor 
symptoms on discontinuing antiparkinson therapy 
and never received r-dopa. The four remaining 
patients eventually received L-dopa 500 mg/day, 
with a 200-mg incremental increase every other 
day to a maximum range of 1.4-2.6 g/day. 
Unfortunately, these four patients had a deterio- 
ration in behavioral status in combination with no 
or minimal reduction in EPS. Overall, the authors 
concluded that L-dopa is not helpful in the treat- 
ment of drug-induced parkinsonism, since it 
exacerbates existing psychotic symptoms without 
relieving EPS. Because of the risk of psychosis, L- 
dopa and bromocriptine are not used to treat 
neuroleptic-induced parkinsonism. ' 9  '9 
The only prodopaminergic drug indicated for the 
treatment of neuroleptic-induced EPS is the 
indirect agonist amantadine. Unlike anticholinergic 
agents, amantadine does not adversely affect 
memory7' or produce autonomic side effects. 
Another advantage is its ability to lower elevated 
prolactin levels, a side effect of neuroleptic agents.82 
In a series of four case reports, amantadine was 
not effective in treating neuroleptic-induced 
akathisia because tolerance developed after 1 week 
of therapy.83 However, most controlled trials 
evaluating amantadine 100-400 mg/day found it to 
be a s  effective as  anticholinergic agents in 
controlling EPS, including parkinsonian symptoms 
and akathisia, with fewer anticholinergic adverse 
e f f e ~ t s . ~ O - ~ ~  Of i mportance, exacerbations of 
psychosis or other detrimental effects on mental 
status were not observed with the small dosages of 
amantadine. Although the frequency of side effects 
caused by amantadine is low, dry mouth,  
excitement, and blurred vision have been reported 
in patients taking this drug for EPSe5 
Summary 
Available data indicate that amantadine has 
similar efficacy as benztropine for parkinsonism 
symptoms, but few data are available concerning 
its use for akathisia, and none regarding its efficacy 
in the treatment of acute dystonic reactions. A 
drawback of amantadine is higher cost compared 
with the more commonly used anticholinergic 
agents. However, because of the lower frequency 
of anticholinergic side effects, amantadine might be 
an attractive alternative in patients who poorly 
tolerate anticholinergics due to such disorders as 
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benign prostatic hyperplasia, narrow-angle 
glaucoma, and pre-existing dementia. 
Benzodiazepines 
Diazepam, lorazepam, and clonazepam have 
been used in the treatment of acute dystonia7’* 
and akathisia4’, 91* 93* 94 with some success. Only a 
single study evaluated their efficacy in the 
treatment of neuroleptic-induced parkins~nism.~~ 
Akathisia 
Akathisia may result from a hypersensitivity of 
the noradrenergic locomotor neurons, which could 
modulate dopaminergc pathways. Benzodiazepines 
may counterbalance increased noradrenergic 
activity through their interaction with inhibitory 
GABA neurons.94 
In an open trial, lorazepam 1.5-5 mg (mean 
dose 2.34 mg) was administered to 16 patients 
with neuroleptic-induced aka th i~ ia .~~ Patients were 
evaluated on days 7 and 14 of therapy using 
clinical observations and a rating scale formulated 
by the  investigator^.^^ Lorazepam reduced (Dunn 
Rankin, p<O.OOl) akathisia scores in nine patients. 
Moderate improvement occurred in five patients, 
and no change was evident in two. Five of the 
patients who improved also received the anticho- 
linergic biperiden, however, making the results 
difficult to interpret. 
In the second open trial, oral clonazepam 0.5 
mg/day was evaluated in 10 young patients (mean 
age 17.1 yrs) who were experiencing distressing 
neuroleptic-induced akathi~ia.~’ Nine patients also 
received benztropine (mean dose 2.8 mg/day range 
2-4 mg/day) during the trial. All patients were 
assessed using the akathisia subscale of the 
Chouinard EPS rating scale (severity scores on 
specific items in this scale may range from 0 = 
absent to 6 = most severe).97 The mean score 
decreased from 4.1 before treatment to 1.6 after 1 
week of treatment (Wilcoxon matched pairs test, 
pc0.005). All 10 patients reported subjective 
improvement. The authors concluded that 
clonazepam, when added to routine antiparkinson 
therapy, effectively controls neuroleptic-induced 
akathisia. 
Akathisia and Dystonia 
Although benzodiazepines are not routinely used 
for dystonia, a single double-blind study yielded 
encouraging results. Diazepam was compared with 
diphenhydramine in patients requiring immediate 
relief from severe acute neuroleptic-induced 
dystonia or a k a t h i ~ i a . ~ ~  Forty intravenous 
treatments were received by 27 patients. Subjects 
were rated on a 4-point scale for dystonia or 
akathisia (0 = no symptoms to 3 = severe 
symptoms) before and a t  5 ,  15, 30, and 120 
minutes after intravenous diazepam or diphen- 
hydramine. Of the 20 patients with dystonia, 10 
received diazepam 5 mg and 10 diphenhydramine 
50 mg. Of the 20 with akathisia, 11 were treated 
with diphenhydramine and 9 with diazepam. Both 
drugs were equally effective in relieving dystonic 
reactions or akathisia symptoms, with a significant 
reduction (paired t test, p<O.Ol) in scale scores 
after 5 minutes. 
Akathisia and Parkinsonism 
In a Japanese study 117 patients with chronic 
schizophrenia being treated with concomitant 
neuroleptic and anti-EPS agents were withdrawn 
from the latter for 6 weeks. During this time 
patients were monitored weekly for signs of either 
neuroleptic-induced akathisia or park ins~nism.~~ 
Patients were scored for akathisia using a 0 
(absent) to 4 (extremely severe) rating scale for 
motor restlessness, internal discomfort, and 
unpleasant sensation. A similar scale (0-4) for 
parkinsonism rated rigidity, akinesia, tremor, 
posture, and gait. At the end of 6 weeks, patients 
who had developed EPS were randomized to 
receive either clonazepam 1 .5  mg/day or a 
resumption of their anti-EPS drug (biperiden, 
trihexyphenidyl, promethazine, prophenamine, 
methixene, or amantadine) using a double-blind 
design, and followed with weekly EPS ratings for 
an additional 6 weeks. If EPS symptoms persisted, 
an additional dose of clonazepam 1.5 mg was 
administered daily. Twelve patients were 
randomized to receive clonazepam, and 10 their 
previous anti-EPS drug. Clonazepam was effective 
in seven of eight patients with akathisia, but in 
only one of the four with parkinsonism. The anti- 
EPS agent was effective for akathisia in four of six 
patients and for parkinsonism in four of five. 
Although the authors concluded that their results 
confirmed the efficacy of clonazepam in the 
treatment of akathisia, no statistical analysis was 
performed, and the study population was too small 
to support this conclusion. 
Summary 
Although the evidence does not convincingly 
support benzodiazepines as first-line agents in the 
treatment of akathisia or dystonia, they might be 
considered in patients with relative contra- 
indications to anticholinergics, such as narrow- 
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angle glaucoma and prostatic hyperplasia. The 
aforementioned studies reported positive results 
with these drugs, but most samples were quite 
small. Also, because some trials administered 
benzodiazepines in conjunction with anti- 
cholinergic agents, it is unclear if benzodiazepines 
work alone or if they potentiate the effects of 
anticholinergics. Since study durations generally 
were short, it is unclear if tolerance develops with 
continued use. Therefore, no firm conclusions 
regarding long-term oral benzodiazepines can be 
drawn based on currently available data, but these 
drugs might be indicated when others fail to 
alleviate dystonia or akathisia. 
P-Adrenergic Blockers in Akathisia 
Currently, although some P-blockers appear to 
be effective in neuroleptic-induced aka th i~ ia ,~~.  45 
not all studies reached that conclusion.98~ 99 The 
mechanism by which the agents reduce akathisia is 
~nclear .~ '  The effects may be mediated through 
PI- or Pz-blockade of receptors located either 
peripherally or centrally5I 
Propranolol 
Propranolol is a highly lipophilic, nonselective 
PI- and P2-receptor antagonist. Most studies 
evaluating the drug in akathisia concluded that it is 
efficacious (Table 3).483 50* 51* 54-583 "', lo' Clinical 
response typically occurs within 1 hour of the first 
dose, and maximum response is usually observed 
within 24-48 51- 5 5  In one direct 
comparison with benztropine, propranolol more 
effectively alleviated symptoms of akathisia."' 
Patients who received benztropine experienced 
some memory impairment, an adverse effect that 
also was documented by other  investigator^.^^^ 
'02-'04 Propranolol effectively treats akathisia, but, 
unfortunately, concomitant parkinsonian symptoms 
remain unaffected. Many patients with neuroleptic- 
induced akathisia also suffer from parkinsonism, 
and thus require an antiparkinsonian agent in 
addition to propranolol. 
Two studies concluded that propranolol is not 
efficacious in the treatment of a k a t h i ~ i a . ~ ~ , ~ ~  In one 
of these trials, a single intravenous dose of 
benztropine was compared with p r o p r a n o l ~ l . ~ ~  
Benztropine reduced both the subjective and 
objective components of akathisia, but propranolol 
was not effective in either of these measures. It is 
possible that the dose of propranolol (1 mg) was 
too small, or that several doses are required in the 
treatment of akathisia. However, since the other 
studies did not directly compare anticholinergic 
agents with propranolol, it cannot be stated 
conclusively that one is superior to the other, 
although anticholinergics probably are effective in 
some proportion of patients. This complicates the 
evaluation of results with propranolol, because in 
a t  least two studies, patients received both 
anticholinergic drugs and propran~lol.~~. 54 
In individual patients i t  can be difficult to 
determine whether motoric restlessness and 
general agitation are due to akathisia or the 
underlying disease state. In one study propranolol 
successfully alleviated both subjective and 
objective ratings of akathisia but did not affect 
anxiety ratings.58 This suggests that akathisia and 
anxiety may be dissociated, and underlying anxiety 
may also require treatment. 
Propranolol 30-80 mg/day shows promising 
results in treating drug-induced akathisia. 
Adverse effects on blood pressure and heart rate 
are minimal at these dosages, but mild wheezing 
occasionally occurs in patients with asthma.51 
Other P-Blockers 
Since most studies agree that propranolol 
effectively treats neuroleptic-induced akathisia, 
investigators have questioned whether similar 
benefits might exist with less lipophilic or more 
cardioselective P-antagonists. Drugs that have been 
studied include betaxolol, a lipophilic &-blocker; 
sotalol, a hydrophilic, nonselective P-blocker; nadolol, 
a hydrophilic, nonselective P-blocker; metoprolol, a 
lipophilic PI-blocker; and atenolol, a hydrophilic PI- 
blocker. 
Metoprolol was compared with propranolol in 
five patients receiving neuroleptics in an open- 
design Both drugs effectively reduced 
akathisia but, even at high dosages, metoprolol 
produced less improvement. Clinically significant 
decreases in mean pulse (17.2 beatdmin) and 
blood pressure (15.2. mm Hg) were also observed 
with metoprolol but not with propranolol. No 
statistical comparisons were performed, but the 
authors concluded that both agents were effective. 
However, metoprolol was effective only in 
controlling akathisia at noncardioselective dosages. 
In addition, since low dosages of propranolol 
alleviated akathisia, but did not produce signs of 
significant peripheral P1-blockade (e.g., reduction 
in pulse rate or blood pressure), it was concluded 
that the antiakathisia mechanism involves either 
central or peripheral P2-receptor blockade. 
In contrast, another study found metoprolol 
efficacious in relieving akathisia at PI-selective 
dosages. lol Nine patients received metoprolol for 
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Table 3. Studies of P-Blockers in Akathisia 
Daily Study 
Dmg Dose (mg) Design No. Results Statistics 
Propranol01~~ 
Propranolol” 
Propranolol 
vs 
benztropinelw 
Prop r a n o 1 o 1 
vs 
lorazepam4* 
Propranolol 
placebo58 
Propranolol 
placebo54 
Propranolol 
placebog8 
Propranolol 
benztropine 
placebo99 
Propranolol 
metoprol01~~ 
Propranolol 
vs 
vs 
vs 
vs 
vs 
vs 
vs 
metoprolol”’ 
Propranolol 
metoprol01~~ 
Propranolol 
atenolo15’ 
vs 
vs 
N a d o 1 o 1 
vs 
placebolo5 
Propranolol 
then sotalol 
30 
30-80 
40-80 
1.5-4 
20-30 
2 
20-60 
60 
60-80 
i.v. doses 
Pro: 1 mg 
Ben: 2 mg 
30-80 
200-400 
40-60 
50-100 
60 
75 
20-60 
25-100 mg 
40-80 
20-40 
40-80 
then betaxololIo6 10-20 
Open 
Open 
Open, 
parallel 
Single-blind, 
crossover 
Double-blind, 
crossover 
Double-blind 
Double-blind 
Single-dose, 
double-blind, 
randomized 
Open, 
crossover 
Open, 
crossover 
Open, 
randomized, 
crossover 
Open, 
crossover 
Double-blind 
Open 
12 
14 
Pro (9) 
Ben (8) 
6 
12 
Pro (10) 
Plb (10) 
Pro (6) 
Plb (5) 
6 
5 
9 
8 
7 
Nad (10) 
Plb (10) 
16 
9/12 complete remission. 
9/14 complete remission. 
50% decrease in objective and 
subjective ratings for Pro; 
no change in objective and 
subjective ratings for Ben 
subjective and objective 
ratings for Pro; improvement 
in objective for Lor. 
Improvement on both subjective 
and objective ratings in 
comparison with Plb. 
Improvement in both 
Pro more effective than Plb on a 
scale measuring both subjective 
and objective features of akathisia. 
Neither group showed any 
improvement in akathisia. 
Global rating scale showed 
improvement for Ben at 15, 
30, and 60 min; Pro showed no 
significant effects. 
Both agents were effective, 
but Pro was more effective. 
Both agents effective in subjective 
and objective measures. 
Both agents effective, but 
those receiving Pro first 
improved more. 
Pro effective on both 
objective and subjective 
scales; Atn not effective. 
Nad not more effective 
than Plb . 
Pro decreased akathisia 
in 8/16; 6 received sotalol, 
and akathisia did not improve 
in any; 4 then received betaxolol 
None performed 
None performed. 
ANOVA. 
Pro: p10.001 over time in 
objective and subjective 
scales. 
ANOVA. 
Pro: objective p=0.001, 
Lor: objective p=0.048. 
ANOVA. 
Pro: p<O.OOl for both 
subjective p=0.017. , 
subjective and objective 
rating scales. 
ANOVA. 
x* p<o.o01. 
No significant differences. 
Ben: p<0.05 global score 
better than Plb at 15,30, 
and 60 min; subjective 
scale better than Plb at 60 
minutes . 
Not performed 
ANOVA. 
Pro: p<0.007. 
Met: p<0.003. 
ANOVA. 
Order by time interaction 
subjective (p<O. 03), 
objective (p<0.04). 
ANOVA 
Pro: p<0.05, improved 
Atn: p<0.05, worse on 
t tests; not significant. 
on both scales. 
both scales. 
Not performed. 
and ill improved. 
Pro = propranolol; Nad = nadolol; Met = metoprolol; Plb = placebo; Atn = atenolol; Ben = benztropine; Lor = lorazepam. 
3-1 1 days and then were directly crossed over to 
propranolol for 3-19 days. Significant improve- 
ments in both subjective and objective measures of 
akathisia occurred with both drugs. In a follow-up 
nonblinded, randomized study, eight patients 
received either propranolol or metoprolol for 1 day, 
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followed by a 1-day washout and crossover to the 
alternative agent for 1 day.56 Both drugs were 
effective, but patients receiving propranolol first 
showed greater improvement. 
Hydrophilic P-blockers are not as successful as 
lipophilic P-blockers in the treatment of akathisia. 
In an open study, atenolol did not control akathisia 
in seven patients when taken for up to 3-4 days.57 
A placebo-controlled, double-blind study of 
nadolol in 20 psychiatric patients with neuroleptic- 
induced akathisia reported no significant 
differences from placebo in either subjective or 
objective assessments, even after 15  days of 
treatment.lo5 This lack of efficacy may be because 
hydrophilic P-blockers do not enter the central 
nervous system as readily as lipophilic P-blockers. 
This suggests that blockade of central P-receptors 
might be necessary to control akathisia. 
The effects of propranolol, sotalol, and betaxolol 
were compared in an open' trial in 16 patients 
suffering from neuroleptic-induced akathisia.'06 
Propranolol was effective in eight patients and led 
to partial improvements in three. Responses 
occurred within 48 hours. The eight responders 
received propranolol for 6 months; six of them 
continued on to phase 11, which was initiated with 
a 2-week washout period, followed by sotalol for 2 
days. None of the six responded to sotalol, even 
when the dosage was increased to 80 mgday. Four 
of these patients then received betaxolol after a 2- 
week washout period, and experienced relief of 
akathisia within 2 days. Since sotalol did not 
relieve symptoms, the authors concluded that 
lipophilic agents such as betaxolol and propranolol 
are likely to be effective through a central P I  
mechanism. Although the results obtained by 
most other l o l ,  lo7 support this 
conclusion, lipophilic PI-specific agents such as 
metoprolol have not always treated akathisia as 
effectively as propran~lol .~~ 
Certain patients may be unable to use P-blockers 
due to underlymg cardiovascular disease. Two case 
reports suggest that pindolol, which has intrinsic 
sympathomimetic activity at dosages of 5 mgday, 
might be an attractive choice for treating 
neuroleptic-induced akathisia in patients with 
sinus bradycardia. '''3 log 
Lipophilic P-blockers, especially propranolol, 
effectively ameliorate symptoms of this disorder. 
Based on currently available reports, propranolol 
30-80 mg/day or metoprolol 50-200 mg/day 
would be the most effective. Unfortunately, in 
many studies, patients also received amantadine, 
anticholinergic agents, or benzodiazepines in 
addition to the P-blockers, drugs that may have 
potentiated the effects of the P-blockers. However, 
these other agents are necessary because they treat 
neuroleptic-induced parkinsonism, whereas P- 
blockers do not. The addition of benzodiazepines 
may be beneficial in treating the inner restlessness 
that often accompanies akathisia but that may not 
respond to P-blockers alone. Although lipophilic 
P-blockers are most effective, further research is 
necessary to determine whether 61- or Pl-receptor 
blockade, or a combination of both, is responsible 
for the beneficial effects. 
Other Agents 
Since P-blockers may work by central adrenergic 
blockade, other drugs with central activity have 
been investigated. Clonidine, an a*-adrenergic 
agonist, is believed to exert its effects by decreasing 
central noradrenergic neurotransmission by 
autoregulation. In an open, on-drugoff-drug trial, 
six patients with drug-induced akathisia received 
clonidine 0.2-0.8 mg/day."O All patients 
improved, and four experienced complete relief. 
The dosage was limited in two patients by postural 
hypotension and sedation. Maximum benefit 
occurred within 24-48 hours. After the drug was 
discontinued, symptoms of akathisia returned to 
pretreatment levels within 24-48 hours. During 
observation for 1 month, no patients developed 
tolerance to clonidine. On the basis of this 
preliminary trial, the authors concluded that 
clonidine may be effective in this disorder, 
although side effects may limit its acceptability. 
A single-blind clonidine study was conducted in 
six schizophrenic patients with akathisia who had a 
rating of at least 1 on a modified Simpson-Angus 
EPS scale."' The dosage was adjusted, based on 
improvement and side effects, from 0.05-0.2 
mgday over 3-15 days, to a maximum of 0.15-0.4 
mgday. All patients had improvement in objective 
and subjective symptoms at maximum dosages 
(paired Student's t test, p<0.005 and p<0.008, 
respectively), and four had improvement in 
subjective symptoms by days 2-4 of the study. 
The upward titration was limited in five patients by 
hypotension, and four patients experienced 
sedation. Clonidine also caused a small but 
significant reduction (paired Student's t test, 
p<0.026) in anxiety, which the authors attributed 
to sedation. Further research might reveal whether 
transdermal administration would be effective and 
associated with fewer side effects. 
Sodium valproate 900-2400 mg/day (mean 
1700 mgday), biperiden 6-18 mgday (mean 12 
mgday), and placebo were evaluated in 15 patients 
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with neuroleptic-induced EPS.69 All patients had 
objective and subjective signs of akathisia, and 11 
also had neuroleptic-induced parkinsonism. All 15 
received each drug for 4 weeks in randomized 
fashion. Overall, sodium valproate did not 
significantly improve akathisia, whereas biperiden 
reduced the symptoms (Wilcoxon's test, p<O.Ol) in 
11 patients. Observed side effects for all three 
agents were minimal, with no significant differences 
among them. However, sodium valproate induced 
parkinsonian symptomatology in seven patients 
without necessarily aggravating akathisia. This 
suggests that the two syndromes may depend on 
different mechanisms. 
Case reports or open trials have been conducted 
with amitriptyline,l12 opioids,'13 and lithium'14 in 
the treatment of neuroleptic-induced akathisia. 
Although the drugs may reduce the symptoms, it is 
difficult to draw any conclusions from the limited 
published data. 
Prophylaxis 
Approximately 90% of acute neuroleptic- 
induced EPS occur within the first 2-3 months of 
therapy27 Because most of these reactions can be 
controlled quickly with anticholinergic or other 
anti-EPS drugs, some clinicians prefer to treat them 
only after they occur.65* 74 Others believe that the 
occurrence of EPS may decrease patient acceptance 
of neuroleptic therapy, and that anti-EPS agents 
should be taken prophylactically for at least the 
first few months of neuroleptic 
Prophylactic antiparkinson therapy to prevent 
neuroleptic-induced EPS is a matter of controversy 
Studies evaluating the initial prophylaxis and 
prevention of EPS were rev ie~ed ."~  At least six 
retrospective studies have been published.24, 25*  38* 60, 
'16, '17 Results were mixed, with three60- 'I6, '17 
concluding that prophylactic anti-EPS drugs are 
unnecessary in the majority of patients, and three24- 
25* 38 stating that they are effective and justified. 
These studies relied heavily on chart review, and 
their designs usually did not include controls or 
randomization; nor were patients assessed with 
clinically validated EPS scales. Consequently, 
conclusions should be based on the results of 
prospective studies. 
Eight prospective studies have been published 
(Table 4)."* 743 118-123 In the largest of these, 202 
newly hospitalized schizophrenic or schizoaffective 
patients were monitored for the occurrence of 
dystonic  reaction^."^ Patients received various 
neuroleptic drugs, including seven high-potency 
and two low-potency agents. Patients were not 
393 6o 
randomized to study groups, nor were the 
investigators or patients blinded to therapy A total 
of 116 patients received prophylaxis, and 86 did 
not. The occurrence of dystonic reactions was not 
significantly different between the groups. Of the 
95 patients who received haloperidol (high- 
potency), however, dystonic reactions were 
significantly more likely to occur in patients in the 
nonprophylaxis group. None of the 33 patients 
receiving low-potency drugs developed dystonic 
reactions. 
Another relatively large study was conducted in 
112 hospitalized patients who were referred, 
without regard to diagnostic category, for neuro- 
leptic treatment due to symptoms of anxiety, agita- 
tion, restlessness, or combativeness.'20 They received 
at least a single tablet daily of either perphenazine 
12 mg or perphenazine 12 mg plus benztropine 
0.75 mg. Only 6 (10%) of 60 patients receiving 
prophylaxis experienced EPS, compared with 17 
(27%) of 62 receiving perphenazine alone. The 
investigators did not include a statistical analysis, 
but a later statistical evaluation reported a 
significant difference (pc0.0 1) in the frequency of 
EPS between the two  group^."^ However, these 
results are confounded by the fact that patients 
receiving perphenazine alone were treated with 
higher dosages (39.5 mg/day) than those who 
received perphenazine plus benztropine (28.7 
mg/day). 
One of the earliest studies evaluated 83 
inpatients (diagnosis not specified) who were given 
either placebo or benztropine while taking one of 
four neuroleptics.12' The study lasted 31 days, 
during which significantly fewer patients who 
received benztropine experienced EPS. Patients 
received low- (chlorpromazine, thioridazine) or 
medium- to high-potency (perphenazine, 
trifluoperazine) phenothiazines, but there was no 
comparison of drug potency or dosage between the 
placebo and benztropine groups. Also, it was not 
stated if patients were neuroleptic free on entering 
the study 
In one of two studies published in 1986,39 newly 
hospitalized, psychotic patients who were receiving 
high-potency neuroleptics (trifluoperazine, 
thiothixene, haloperidol, or fluphenazine) were 
given a 7-day course of placebo or benz t r~pine .~~ 
Based on medical charti and nursing reports, 
significantly more patients receiving placebo 
developed acute dystonic reactions. The authors 
concluded that 7 days of benztropine prophylaxis 
was associated with a decreased frequency of acute 
dystonic reactions without a significant increase in 
anticholinergic side effects, but the daily dose of 
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Table 4. Prospective Studies of the Prophylaxis of EPS 
Daily 
Statistics Drugs Dose (mg) Design Results 
Overall, patients in the prophylaxis Various neuroleptics + 
benztropine (n=109) 
trihexyphenidyl (n=3) 
diphenhydramine (n=4) 
no prophylaxis (n=86)'19 
Perphenazine alone (n=62) 
Perphenazine + 
benztropine (n=60)12' 
Various neuroleptics + 
benztropine (n=42) 
placebo (n=41)121 
High-potency neuroleptics + 
benztropine (n=22) 
placebo (r1=17)~~ 
Various neuroleptics + 
trihexyphenidyl (n=15) 
placebo (t1=27)'~~ 
Haloperidol + 
benztropine (n=14) 
placebo (n=15)12' 
Flupenthixol + 
procyclidine (n=18) 
placebo (r1=18)'~ 
Haloperidol alone (n=lO) 
Haloperidol + 
Haloperidol + 
procyclidine (n=10) 
promethazine (n= 13)"* 
2-4 
6-15 
75-150 
1.79 
? 
4 
7.5-15 
4 
15 
15 mg 
75 mg 
Open 
Double-blind, 
randomized 
Double-blind, 
randomized 
Double-blind, 
randomized 
Double-blind, 
randomized 
Double-blind, 
randomized 
Double-blind, 
randomized 
?Single-blind, 
randomized 
group had similar number of 
dystonic reactions as the no-prophy- 
laxis group; but in the group that 
received haloperidol, fewer dystonic 
reactions with prophylaxis. 
After 6 wks, patients receiving 
prophylaxis experienced less EPS. 
1/42 patients receiving prophylaxis 
suffered EPS, but 13/41 receiving 
placebo suffered EPS. 
0/22 patients receiving benztropine 
developed dystonic reactions, but 
8/17 receiving placebo had dystonic 
reactions within 48 hours of first 
neuroleptic dose. 
More patients dropped out in the 
placebo group; the prophylaxis group 
exhibited less akinesia and sialorrhea. 
2/14 patients taking benztropine and 
5/15 patients taking placebo suffered 
dystonic reactions within 7 days; 3 
additional patients had dystonic 
reactions when benztropine was 
discontinued. 
One patient receiving procyclidine 
and 6 patients in the placebo group 
~ 
All patients: 
Haloperidol (only): 
x2 = 1.76, p>O.l. 
x2 = 7.86, p<0.005. 
Not performed. 
Significant difference 
p<O.Ol, patients 
receiving benztropine 
suffering less EPS. 
x2 = p<O.002 in favor of 
benztropine. 
p<O.OOl, significant 
difference in early 
termination; akinesia, 
pd.05; sialorrhea, pd.01. 
reactions in first 7 days, 
NS. 
Difference in dystonic 
Kruskal-Wallis p<0.02 
overaU total of separately 
scored EPS items. required supplementary procyclidine; 
overall, placebo group exhibited more EPS. 
haloperidol (alone) group; 3/13 dropped 
out of the haloperidol + promethazine 
group, and none dropped from the 
haloperidol + procyclidine group. 
7/10 patients dropped out of the No significant differences 
were found between the 
haloperidol + prometh- 
azine and the haloperidol 
+ procyclidine groups; 
haloperidol alone was 
not included in analvsis. 
benztropine (4 mg) was relatively low. 
Also in 1986, 42 psychotic outpatients received 
either placebo or trihexyphenidyl in combination 
with their neuroleptic agents.122 For comparison, 
patients were evaluated weekly using the 10-item 
Simpson-Angus scale that rates the severity of 
primarily parkinsonian symptoms from 0 to 4. 124 
Patients receiving trihexyphenidyl had significantly 
less akinesia and sialorrhea than those receiving no 
prophylaxis. Unfortunately, the dosages of 
neuroleptics were not compared. 
Prophylaxis with benztropine was evaluated in 
29 patients with schizophrenia, bipolar disease 
(manic), atypical psychosis, or schizoaffective 
di~0rder . I~~ Patients were treated with haloperidol 
(mean dose f SD 14.1 + 3.3 mg) and also received 
lorazepam to control anxiety They then received 
benztropine or matching placebo for the first 7 
days of the study, followed by open-label dosing of 
benztropine on an as-needed basis to control 
dystonia on days 8-14. A single evaluator assessed 
patients twice a day for EPS using the Simpson- 
Angus EPS scale.124 Overall, fewer patients in the 
benztropine group experienced dystonic reactions, 
but the difference was not statistically significant. 
The sample was very small, and the concurrent 
administration of lorazepam may have influenced 
the overall frequency of dystonic reactions. 
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In the only prospective study that did not 
conclude that prophylactic anti-EPS treatment is 
warranted, 36 schizophrenic inpatients were given 
an oral neuroleptic, flupenthixol, for 10 days 
before the addition of placebo or procyclidine for 
an additional 18 days.74 The EPS were rated before 
any drug, and then twice a week for the duration 
(18 days) using a seven-item scale developed by 
the investigators that scored restlessness, 
choreiform dyskinesia, rigidity in both face and 
upper body, tremor, and gait disturbance using 
values from 1-4 (absent-severe). Although the 
overall total of the separately scored EPS items was 
significantly lower in the procyclidine group, the 
investigators discouraged routine EPS prophylaxis 
with anticholinergic agents because they also found 
that psychotic symptoms did not respond as well 
when patients received procyclidine. 
The consequences of withdrawal of prophylactic 
anti-EPS drugs during long-term neuroleptic 
treatment is an equally controversial topic. 125 
Although the results of double-blind, placebo- 
controlled studies generally indicated that some 
proportion of patients receiving neuroleptics suffer 
from a recrudescence of EPS on discontinuing anti- 
EPS agents, considerable disagreement exists 
regarding the actual proportion of patients who 
require continuous anti-EPS therapy and how long 
the drugs should be given before a trial discon- 
tinuation is attempted. 
Only four studies that addressed discontinuing 
anti-EPS therapy specified the duration of 
concomitant neuroleptic treatment before 
disc~ntinuation.~~- 12w2' In all four the duration of 
combined therapy was at least 3 months. Three of 
the studies discouraged long-term anti-EPS therapy. 
One reported that only 18% of patients switched 
from anti-EPS agents to placebo required 
resumption of anti-EPS treatment.65 In another 
study 50% of patients switched from an anti-EPS 
drug to placebo required a return to active 
treatment, but the authors still concluded that long- 
term therapy was warranted only if EPS actually 
occurred, and that patients should be assessed 
frequently for the necessity of continued therapy. 126 
In 42 patients with chronic schizophrenia who had 
been treated with combined neuroleptics and anti- 
EPS agents for at  least 3 months, the change in 
severity of EPS did not differ significantly whether 
they were switched to placebo or continued their 
previous anti-EPS drug. 12' 
In the one study in which continued combined 
use of neuroleptics and anti-EPS agents was 
deemed necessary, 98  patients with chronic 
schizophrenia were randomized to receive placebo 
(75%) or trihexyphenidyl 7.5-20 mg/day (25%).12' 
Patients were monitored weekly for 6 weeks. In 
the placebo group, 51 of 75 patients required early 
termination, and another 21 had some less severe 
worsening of EPS. In contrast, 20 of 23 patients in 
the trihexyphenidyl group had no worsening of 
EPS. The difference was statistically significant 
Overall, these studies reported that anywhere 
from 10-68% of patients may require resumption 
of anti-EPS agents after withdrawal when they have 
received concomitant drugs for at least 3 months. 
However, it was unclear in most of them whether 
patients were given the drugs prophylactically or 
because they had exhibited EPS. The results seem 
to suggest that a trial without treatment is probably 
warranted after 3 months, especially if it is unclear 
why therapy was initiated. 
In most studies anti-EPS agents were withdrawn 
abruptly, and it is possible that some symptoms 
that could be attributed to anticholinergic with- 
drawal might have contributed to the need to resume 
them. To evaluate this possibility, anticholinergic 
agents were tapered during two of the withdrawal 
s t u d i e ~ . ' ~ ~ ~ ' ~ ~  In neither case did this appear to 
affect the proportion of patients requiring resump- 
tion of treatment. 
Patients often receive anti-EPS drugs for the 
duration of treatment with an antipsychotic, even 
though evidence suggests that, in a large percent- 
age of such patients, this is unne~essary.~~ A trial 
period off anti-EPS therapy after about 3 months 
appears to be indicated in the majority of cases. If 
EPS should recur, they can be controlled quickly 
by reinitiating the 60, 65 The available data 
suggest that the best approach to anti-EPS pro- 
phylaxis is to individualize therapy. If clinicians 
are concerned that the development of an acute 
dystonic reaction might alarm the patient, leading to 
future compliance problems, prophylaxis might be 
beneficial.60 Patients with a history of EPS, especial- 
ly dystonic reactions, are most likely to benefit.131 
(p<O.OO 1). 
Conclusion 
Acute EPS are common during treatment with 
drugs that block dopamine receptors. Although 
these syndromes are to some degree dose 
dependent, they are aho quite patient specific. 
Direct approaches to treatment include decreasing 
the dosage of the responsible agent and switching 
to a neuroleptic agent with greater anticholinergic 
effects. When a particular neuroleptic has resulted 
in a good therapeutic response, the clinician may 
not be able to decrease the dosage and may not 
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wish to switch to a different drug. In such cases a 
more appropriate alternative is to administer an 
agent to alleviate the EPS. 
Anticholinergic agents are most commonly used, 
and they all appear to have equivalent efficacy. 
Both parkinsonism and acute dystonic reactions 
respond well, and akathisia is alleviated in a 
reasonable proportion of patients. These factors, 
and the relatively low acquisition cost of anti- 
cholinergics, make them the first line of treatment 
for all types of EPS. However, it should be remem- 
bered that they may potentiate anticholinergic 
adverse effects when given in combination with 
neuroleptic agents. Dosages in the lower part of 
the recommended ranges should be chosen in the 
elderly or other patients who are likely to show 
high sensitivity to anticholinergic effects. 
Amantadine is less commonly administered and 
more costly than the anticholinergic agents. It 
effectively treats parkinsonism and should be 
considered as second-line therapy, particularly in 
patients who cannot tolerate anticholinergic effects. 
Benzodiazepines appear to attenuate both acute 
dystonia and akathisia. Information is not 
available on *their long-term efficacy in treating 
these syndromes, and long-term use is accom- 
panied by the risk of physical dependence. Since 
no evidence exists that benzodiazepines effectively 
treat parkinsonism, they should be reserved for 
patients in whom akathisia is resistant to anti- 
cholinergc drugs. It is unlikely that benzodiazepines 
will ever be widely used in the treatment of acute 
dystonic reactions because the anticholinergics 
appear to be universally effective in this disorder. 
The P-blockers, specifically propranolol, may 
effectively treat akathisia, but they are not effective 
for either acute dystonic reactions or parkinsonism. 
They should be considered as the second choice 
for akathisia in patients who do not respond to, or 
are intolerant of, anticholinergic agents. They 
should be avoided in patients with a history of 
asthma, and regular monitoring of blood pressure 
is highly recommended. 
N o  consensus exists concerning the most 
appropriate prophylaxis or duration of therapy 
with the anti-EPS drugs. Perhaps the best strategy 
would be prophylactic administration in patients 
who previously suffered acute EPS, and as 
necessary in other patients. Available data also 
support a trial discontinuation of anti-EPS therapy 
after 3 months, reinitiating it if necessav. 
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